Javascript must be enabled to continue!
Evaluation of Metabolic Effects of Nusinersen in Patients with Spinal Muscular Atrophy
View through CrossRef
AbstractNusinersen is the first disease-modifying therapy for spinal muscular atrophy (SMA), but there are few data on potential long-term endocrinological and metabolic systemic effects of this novel treatment as well as metabolic alterations in SMA itself. In this retrospective and multicentric study, we analyzed anthropometric, endocrinological, and motor function data of 81 pediatric and adult patients with SMA1 to 3 undergoing treatment with nusinersen. In 39 patients (51%), we observed a slight increase in body mass index (BMI) centiles under treatment with nusinersen, especially in patients with SMA2 and in pediatric patients between 3.1 and 12 years. A correlation to the SMN2 copy number or motor function was not found. Additionally, length centiles decreased significantly under treatment. The results of longitudinal endocrinological assessments were interpreted as not clinically significant in most patients; in three patients, the signs of an altered glucose metabolism were present. Our study indicates a putative effect of treatment with nusinersen on BMI, which might be due to a conjoint effect of weight gain and reduction of height velocity, without evidence of correlation to increased muscle function. Further studies need to address specific effects of targeted therapies such as nusinersen or onasemnogene abeparvovec on body composition including fat and muscle mass.
Necmettin Erbakan University Press
Title: Evaluation of Metabolic Effects of Nusinersen in Patients with Spinal Muscular Atrophy
Description:
AbstractNusinersen is the first disease-modifying therapy for spinal muscular atrophy (SMA), but there are few data on potential long-term endocrinological and metabolic systemic effects of this novel treatment as well as metabolic alterations in SMA itself.
In this retrospective and multicentric study, we analyzed anthropometric, endocrinological, and motor function data of 81 pediatric and adult patients with SMA1 to 3 undergoing treatment with nusinersen.
In 39 patients (51%), we observed a slight increase in body mass index (BMI) centiles under treatment with nusinersen, especially in patients with SMA2 and in pediatric patients between 3.
1 and 12 years.
A correlation to the SMN2 copy number or motor function was not found.
Additionally, length centiles decreased significantly under treatment.
The results of longitudinal endocrinological assessments were interpreted as not clinically significant in most patients; in three patients, the signs of an altered glucose metabolism were present.
Our study indicates a putative effect of treatment with nusinersen on BMI, which might be due to a conjoint effect of weight gain and reduction of height velocity, without evidence of correlation to increased muscle function.
Further studies need to address specific effects of targeted therapies such as nusinersen or onasemnogene abeparvovec on body composition including fat and muscle mass.
Related Results
SPINAL MUSCULAR ATROPHY CLINICAL FEATURES, CLASSIFICATION, NATURAL HISTORY, GENETICS, DIAGNOSIS, COMPLICATIONS AND TREATMENT OF THE DISEASE
SPINAL MUSCULAR ATROPHY CLINICAL FEATURES, CLASSIFICATION, NATURAL HISTORY, GENETICS, DIAGNOSIS, COMPLICATIONS AND TREATMENT OF THE DISEASE
Introduction: Spinal muscular atrophy (SMA) is a complex neuromuscular disorder, it is the most usual autosomal recessively inherited lethal neuromuscular disease in pediatrics, it...
Therapy of Spinal Muscular Atrophy at the Present Stage: a Review
Therapy of Spinal Muscular Atrophy at the Present Stage: a Review
INTRODUCTION. Spinal muscular atrophy (SMA) is a group of hereditary neuromuscular diseases that primarily affect infants and children. It is caused by a mutation in the gene encod...
Increased Chitotriosidase1 Concentration Following Nusinersen Treatment in Spinal Muscular Atrophy
Increased Chitotriosidase1 Concentration Following Nusinersen Treatment in Spinal Muscular Atrophy
Abstract
BackgroundStudies regarding the impact of (neuro)inflammation and inflammatory response following repetitive, intrathecally administered antisense oligonucleotides...
Axonal excitability changes in children with spinal muscular atrophy treated with nusinersen
Axonal excitability changes in children with spinal muscular atrophy treated with nusinersen
AbstractSpinal muscular atrophy (SMA) is associated with developmental disruption of motor axons in ventral roots of the spinal cord alongside motor axon degeneration. The pathogen...
Using Cerebrospinal Fluid Improves Detection of Individual Brain Atrophy
Using Cerebrospinal Fluid Improves Detection of Individual Brain Atrophy
Abstract
Background
Clinical neuroradiologists routinely look for expansion of CSF spaces to help identify atrophy on patient MRI scans. In contrast, automated methods for...
Spinal Cord Injury Rehabilitation: Basics and Beyond
Spinal Cord Injury Rehabilitation: Basics and Beyond
This special issue is dedicated to the Borneo International Spinal Cord Injury (SCI) Rehabilitation Conference (BISCIR) which was held on 30th July – 1st August 2021 through a virt...
Spinal Cord Injury Rehabilitation: Basics and Beyond
Spinal Cord Injury Rehabilitation: Basics and Beyond
This special issue is dedicated to the Borneo International Spinal Cord Injury (SCI) Rehabilitation Conference (BISCIR) which was held on 30th July – 1st August 2021 through a virt...
O Processo de Incorporação do Nusinersena ao Sistema Único de Saúde para Tratamento da Atrofia Muscular Espinhal
O Processo de Incorporação do Nusinersena ao Sistema Único de Saúde para Tratamento da Atrofia Muscular Espinhal
A Atrofia Muscular Espinhal (AME) é uma doença neurodegenerativa, na qual o gene SMN1 não é expresso, caracterizada por fraqueza muscular, paralisia e dificuldades respiratórias. T...

